{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:27:35Z","timestamp":1792520855973,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"DOI":"10.1007\/s40264-026-01726-x","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:47:10Z","timestamp":1789638430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interpreting Positive and Inverse Disproportionality Signals in Spontaneous Reporting Systems: A Claim-Strength Framework with Direction-Aware Evaluation"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5773-991X","authenticated-orcid":false,"given":"Yoshihiro","family":"Uesawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"6","key":"1726_CR1","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136. https:\/\/doi.org\/10.1002\/pds.677.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"1726_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336. https:\/\/doi.org\/10.1002\/pds.1742.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1726_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"JL Faillie","year":"2019","unstructured":"Faillie JL. Case\u2013non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74(2):225\u201332. https:\/\/doi.org\/10.1016\/j.therap.2019.01.006.","journal-title":"Therapie"},{"key":"1726_CR4","unstructured":"U.S. Food and Drug Administration. FDA Adverse Event Monitoring System (AEMS) Public Dashboard [formerly FDA Adverse Event Reporting System (FAERS)]. https:\/\/www.fda.gov\/drugs\/fda-adverse-event-monitoring-system-aems\/fda-adverse-event-monitoring-system-aems-public-dashboard. Accessed 13 July 2026."},{"key":"1726_CR5","unstructured":"European Medicines Agency. EudraVigilance system overview. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/pharmacovigilance-research-development\/eudravigilance\/eudravigilance-system-overview. Accessed 5 May 2026."},{"key":"1726_CR6","unstructured":"Uppsala Monitoring Centre. About VigiBase. https:\/\/who-umc.org\/vigibase-data-access\/about-vigibase\/. Accessed 5 May 2026."},{"key":"1726_CR7","unstructured":"Pharmaceuticals and Medical Devices Agency. Japanese Adverse Drug Event Report database (JADER): terms of use. https:\/\/www.pmda.go.jp\/safety\/info-services\/drugs\/adr-info\/suspected-adr\/0003.html. Accessed 5 May 2026."},{"key":"1726_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, B\u00e9gaud B, et al. The REporting of A disproportionality analysis for drUg safety signal detection using individual case safety reports in pharmacoVigilance (READUS-PV): development and statement. Drug Saf. 2024;47:575\u201384. https:\/\/doi.org\/10.1007\/s40264-024-01421-9.","journal-title":"Drug Saf"},{"key":"1726_CR9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, B\u00e9gaud B, et al. The REporting of A disproportionality analysis for drUg safety signal detection using individual case safety reports in pharmacoVigilance (READUS-PV): explanation and elaboration. Drug Saf. 2024;47:585\u201399. https:\/\/doi.org\/10.1007\/s40264-024-01423-7.","journal-title":"Drug Saf"},{"key":"1726_CR10","doi-asserted-by":"publisher","first-page":"175628642412768","DOI":"10.1177\/17562864241276847","volume":"17","author":"C Khouri","year":"2024","unstructured":"Khouri C, Hlavaty A, Revol B, Salvo F, Raschi E. Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database. Ther Adv Neurol Disord. 2024;17:17562864241276848. https:\/\/doi.org\/10.1177\/17562864241276847.","journal-title":"Ther Adv Neurol Disord"},{"key":"1726_CR11","doi-asserted-by":"publisher","first-page":"e430","DOI":"10.1111\/jdv.16379","volume":"34","author":"E Raschi","year":"2020","unstructured":"Raschi E, Salvo F, La Placa M, Poluzzi E, De Ponti F. Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction. J Eur Acad Dermatol Venereol. 2020;34:e430\u20131. https:\/\/doi.org\/10.1111\/jdv.16379.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1726_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.bbi.2019.11.011","volume":"84","author":"E Raschi","year":"2020","unstructured":"Raschi E, Poluzzi E, De Ponti F. Reduced neuropsychiatric events as \u201cbeneficial reactions\u201d to drugs: seek associations with caution. Brain Behav Immun. 2020;84:275\u20136. https:\/\/doi.org\/10.1016\/j.bbi.2019.11.011.","journal-title":"Brain Behav Immun"},{"issue":"1","key":"1726_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00592-019-01441-3","volume":"57","author":"IC Antonazzo","year":"2020","unstructured":"Antonazzo IC, Poluzzi E, Forcesi E, Salvo F, Pariente A, Marchesini G, et al. Signal of potentially protective drug\u2013drug interactions from spontaneous reporting systems: proceed with caution. Acta Diabetol. 2020;57(1):115\u20136. https:\/\/doi.org\/10.1007\/s00592-019-01441-3.","journal-title":"Acta Diabetol"},{"issue":"4","key":"1726_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315\u201321. https:\/\/doi.org\/10.1007\/s002280050466.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1726_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W DuMouchel","year":"1999","unstructured":"DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53(3):177\u201390. https:\/\/doi.org\/10.1080\/00031305.1999.10474456.","journal-title":"Am Stat"},{"key":"1726_CR16","doi-asserted-by":"publisher","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","volume":"3","author":"PM Cutroneo","year":"2024","unstructured":"Cutroneo PM, Sartori D, Tuccori M, Crisafulli S, Battini V, Carnovale C, et al. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front Drug Saf Regul. 2024;3:1323057. https:\/\/doi.org\/10.3389\/fdsfr.2023.1323057.","journal-title":"Front Drug Saf Regul."},{"key":"1726_CR17","unstructured":"World Health Organization. The use of the WHO-UMC system for standardised case causality assessment. Geneva: World Health Organization; 2013.\u00a0https:\/\/www.who.int\/publications\/m\/item\/WHO-causality-assessment. Accessed 5 May 2026."},{"issue":"396","key":"1726_CR18","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/01621459.1986.10478354","volume":"81","author":"PW Holland","year":"1986","unstructured":"Holland PW. Statistics and causal inference. J Am Stat Assoc. 1986;81(396):945\u201360. https:\/\/doi.org\/10.1080\/01621459.1986.10478354.","journal-title":"J Am Stat Assoc"},{"key":"1726_CR19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente A, Gr\u00e9goire F, Fourrier-R\u00e9glat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30:891\u20138. https:\/\/doi.org\/10.2165\/00002018-200730100-00007.","journal-title":"Drug Saf"},{"key":"1726_CR20","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/BF03261981","volume":"35","author":"A Pariente","year":"2012","unstructured":"Pariente A, Avillach P, Salvo F, et al. Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France. Drug Saf. 2012;35:855\u201364. https:\/\/doi.org\/10.1007\/BF03261981.","journal-title":"Drug Saf"},{"key":"1726_CR21","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40264-013-0063-5","volume":"36","author":"F Salvo","year":"2013","unstructured":"Salvo F, Leborgne F, Thiessard F, et al. A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France. Drug Saf. 2013;36:565\u201372. https:\/\/doi.org\/10.1007\/s40264-013-0063-5.","journal-title":"Drug Saf"},{"key":"1726_CR22","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40264-024-01433-5","volume":"47","author":"CA Gravel","year":"2024","unstructured":"Gravel CA, Bai W, Douros A. Comparators in pharmacovigilance: a quasi-quantification bias analysis. Drug Saf. 2024;47:809\u201319. https:\/\/doi.org\/10.1007\/s40264-024-01433-5.","journal-title":"Drug Saf"},{"issue":"8","key":"1726_CR23","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758\u201364. https:\/\/doi.org\/10.1093\/aje\/kwv254.","journal-title":"Am J Epidemiol"},{"key":"1726_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3532","volume":"363","author":"SM Langan","year":"2018","unstructured":"Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ. 2018;363:k3532. https:\/\/doi.org\/10.1136\/bmj.k3532.","journal-title":"BMJ"},{"key":"1726_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2026.107113","volume":"109","author":"M Asada","year":"2026","unstructured":"Asada M, Aizawa F, Mikami T, Goda M, Sonoda Y, Niimura T, et al. Bile acids as candidate therapies for multiple sclerosis: inverse signal analysis using the FDA Adverse Event Reporting System and preclinical validation. Mult Scler Relat Disord. 2026;109:107113. https:\/\/doi.org\/10.1016\/j.msard.2026.107113.","journal-title":"Mult Scler Relat Disord."},{"issue":"206","key":"1726_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006548","volume":"5","author":"S Zhao","year":"2013","unstructured":"Zhao S, Nishimura T, Chen Y, et al. Systems pharmacology of adverse event mitigation by drug combinations. Sci Transl Med. 2013;5(206):206ra140. https:\/\/doi.org\/10.1126\/scitranslmed.3006548.","journal-title":"Sci Transl Med"},{"key":"1726_CR27","doi-asserted-by":"publisher","first-page":"26375","DOI":"10.1038\/srep26375","volume":"6","author":"T Nagashima","year":"2016","unstructured":"Nagashima T, Shirakawa H, Nakagawa T, Kaneko S. Prevention of antipsychotic-induced hyperglycaemia by vitamin D: a data mining prediction followed by experimental exploration of the molecular mechanism. Sci Rep. 2016;6:26375. https:\/\/doi.org\/10.1038\/srep26375.","journal-title":"Sci Rep"},{"key":"1726_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204648","volume":"13","author":"K Hosomi","year":"2018","unstructured":"Hosomi K, Fujimoto M, Ushio K, et al. An integrative approach using real-world data to identify alternative therapeutic uses of existing drugs. PLoS ONE. 2018;13:e0204648. https:\/\/doi.org\/10.1371\/journal.pone.0204648.","journal-title":"PLoS ONE"},{"issue":"11","key":"1726_CR29","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1111\/bcp.14868","volume":"87","author":"R B\u00f6hm","year":"2021","unstructured":"B\u00f6hm R, Bulin C, Waetzig V, Cascorbi I, Klein HJ, Herdegen T. Pharmacovigilance-based drug repurposing: the search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections. Br J Clin Pharmacol. 2021;87(11):4421\u201331. https:\/\/doi.org\/10.1111\/bcp.14868.","journal-title":"Br J Clin Pharmacol"},{"key":"1726_CR30","doi-asserted-by":"publisher","first-page":"1159453","DOI":"10.3389\/fmed.2023.1159453","volume":"10","author":"M Ko","year":"2023","unstructured":"Ko M, Oh JM, Kim I-W. Drug repositioning prediction for psoriasis using the adverse event reporting database. Front Med (Lausanne). 2023;10:1159453. https:\/\/doi.org\/10.3389\/fmed.2023.1159453.","journal-title":"Front Med (Lausanne)."},{"issue":"4","key":"1726_CR31","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2008;167(4):492\u20139. https:\/\/doi.org\/10.1093\/aje\/kwm324.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"1726_CR32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3820\/jjpe.25.64","volume":"25","author":"T Sakai","year":"2020","unstructured":"Sakai T. A checklist of important points in research using JADER. Jpn J Pharmacoepidemiol (Yakuzai Ekigaku). 2020;25(2):64\u201373. https:\/\/doi.org\/10.3820\/jjpe.25.64.","journal-title":"Jpn J Pharmacoepidemiol (Yakuzai Ekigaku)."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01726-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01726-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01726-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:47:14Z","timestamp":1789638434000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01726-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":32,"alternative-id":["1726"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01726-x","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"9 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no financial competing interests. For transparency, the author was a coauthor of one empirical precedent cited in this review [\n                      \n                      ]. That study is presented as an illustrative preclinical precedent and not as independent clinical, epidemiological, or causal validation. No other relevant non-financial competing interests are declared.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yoshihiro Uesawa: Conceptualization, methodology, literature interpretation, writing\u2014original draft, writing\u2014review and editing, supervision, and final approval of the manuscript.","order":2,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article is a narrative methodological review and does not involve human participants, animals, or identifiable personal data.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing is not applicable to this article because no new datasets were generated or analyzed.","order":6,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}